IL145506A0 - A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate - Google Patents
A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonateInfo
- Publication number
- IL145506A0 IL145506A0 IL14550600A IL14550600A IL145506A0 IL 145506 A0 IL145506 A0 IL 145506A0 IL 14550600 A IL14550600 A IL 14550600A IL 14550600 A IL14550600 A IL 14550600A IL 145506 A0 IL145506 A0 IL 145506A0
- Authority
- IL
- Israel
- Prior art keywords
- bisphosphonate
- pharmaceutical formulation
- additive agent
- agent providing
- enhanced absorption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
| PCT/SE2000/000664 WO2000061111A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL145506A0 true IL145506A0 (en) | 2002-06-30 |
Family
ID=20415159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14550600A IL145506A0 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1171097A1 (en) |
| JP (1) | JP2002541185A (en) |
| KR (1) | KR20010104389A (en) |
| AU (1) | AU4161900A (en) |
| CA (1) | CA2364659A1 (en) |
| IL (1) | IL145506A0 (en) |
| NO (1) | NO20014895L (en) |
| NZ (1) | NZ514478A (en) |
| SE (1) | SE9901272D0 (en) |
| WO (1) | WO2000061111A1 (en) |
| ZA (1) | ZA200108260B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| CN1446093A (en) | 2000-04-07 | 2003-10-01 | 得克萨斯系统大学董事会 | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| MXPA02010740A (en) * | 2000-05-05 | 2003-03-10 | Hoffmann La Roche | Gel like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts. |
| WO2002070438A2 (en) * | 2001-03-01 | 2002-09-12 | Emisphere Technologies, Inc. | Compositions for delivering bisphosphonates |
| JP4381805B2 (en) | 2001-07-02 | 2009-12-09 | メリオン リサーチ スリー リミテッド | Delivery of bioactive materials |
| EP2851105A1 (en) | 2002-05-10 | 2015-03-25 | F. Hoffmann-La Roche AG | Bisphosphonic acids for treatment and prevention of osteoporosis |
| NZ536273A (en) | 2002-12-20 | 2007-08-31 | Hoffmann La Roche | High dose ibandronate formulation |
| EP1583768B1 (en) * | 2003-01-17 | 2008-07-30 | Teva Pharmaceutical Industries Limited | Method for reducing the iron content of risedronate sodium |
| GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| US8637503B2 (en) | 2003-05-16 | 2014-01-28 | Board Of Regents, The University Of Texas System | Phenothiazine enantiomers as agents for the prevention of bone loss |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| MY144704A (en) * | 2004-05-24 | 2011-10-31 | Procter & Gamble | Dosage forms of bisphosphonates |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
| KR100815040B1 (en) * | 2005-01-31 | 2008-03-18 | 주식회사종근당 | Pharmaceutical compositions containing bisphosphonate for improving oral absorption |
| NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
| BRPI0710503A2 (en) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form |
| GB0616794D0 (en) | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| KR20110007242A (en) | 2008-05-07 | 2011-01-21 | 메리온 리서치 Ⅲ 리미티드 | Compositions of peptides and processes of preparation thereof |
| CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| KR101631243B1 (en) * | 2009-05-13 | 2016-06-17 | 신일제약주식회사 | Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same |
| JP5852569B2 (en) | 2009-07-31 | 2016-02-03 | タール ファーマシューティカルズ，インコーポレイテッド | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| FR2954320B1 (en) | 2009-12-17 | 2012-06-15 | Cll Pharma | SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | Pharmaceutical compositions of iron for oral administration |
| KR20120105738A (en) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | An enteric-coated oral formulation |
| JP5874545B2 (en) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| WO2017007777A2 (en) * | 2015-07-06 | 2017-01-12 | Zhengxin Dong | NOVEL FORMULATIONS OF PTHrP ANALOGUE |
| EP3455229B1 (en) * | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN112972400A (en) * | 2021-03-09 | 2021-06-18 | 华侨大学 | Rapidly disintegrable minodronic acid granules and preparation method thereof |
| KR20240013402A (en) * | 2022-07-22 | 2024-01-30 | 주식회사 아이큐어비앤피 | Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
| EP0550385A1 (en) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers |
| TW237386B (en) * | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
| SE501389C2 (en) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Pharmaceutical preparation and process for its preparation |
| UA39884C2 (en) * | 1993-05-15 | 2001-07-16 | Рош Діагностікс, Гмбх | CLODRONIC ACID-BASED TABLET, METHOD OF PRODUCTION AND TREATMENT OF OSTEOPOROSIS |
| IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| FI109088B (en) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tablet and process for its preparation |
| SE9703691D0 (en) * | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-04-09 SE SE9901272A patent/SE9901272D0/en unknown
-
2000
- 2000-04-06 NZ NZ514478A patent/NZ514478A/en unknown
- 2000-04-06 KR KR1020017012793A patent/KR20010104389A/en not_active Application Discontinuation
- 2000-04-06 AU AU41619/00A patent/AU4161900A/en not_active Abandoned
- 2000-04-06 IL IL14550600A patent/IL145506A0/en unknown
- 2000-04-06 CA CA002364659A patent/CA2364659A1/en not_active Abandoned
- 2000-04-06 WO PCT/SE2000/000664 patent/WO2000061111A1/en active Search and Examination
- 2000-04-06 JP JP2000610444A patent/JP2002541185A/en active Pending
- 2000-04-06 EP EP00921288A patent/EP1171097A1/en not_active Withdrawn
-
2001
- 2001-10-08 ZA ZA200108260A patent/ZA200108260B/en unknown
- 2001-10-08 NO NO20014895A patent/NO20014895L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002541185A (en) | 2002-12-03 |
| ZA200108260B (en) | 2003-03-26 |
| NZ514478A (en) | 2004-01-30 |
| EP1171097A1 (en) | 2002-01-16 |
| NO20014895L (en) | 2001-12-10 |
| NO20014895D0 (en) | 2001-10-08 |
| CA2364659A1 (en) | 2000-10-19 |
| SE9901272D0 (en) | 1999-04-09 |
| WO2000061111A1 (en) | 2000-10-19 |
| KR20010104389A (en) | 2001-11-24 |
| AU4161900A (en) | 2000-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL145506A0 (en) | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate | |
| PL351526A1 (en) | Pharmaceutical formulation comprising amoxycillin | |
| IL144977A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
| EG24066A (en) | Novel quinuclidine derivatives and medicinal compositions containing the same | |
| HK1040995A1 (en) | 2-oxoquinoline compounds and medicinal uses thereof | |
| HK1061037A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
| PL343491A1 (en) | Pharmaceutical aerosol formulation | |
| IL150383A0 (en) | Glyburide and pharmaceutical compositions containing the same | |
| PT1200118E (en) | A pharmaceutical formulation comprising megalatran and its prodrug | |
| IL147214A0 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same | |
| IL148807A0 (en) | Tetrahydrothiopyran derivatives and pharmaceutical compositions containing the same | |
| HUP0200055A3 (en) | 16-hydroxyestrienes and pharmaceutical compositions containing the same | |
| GB9818927D0 (en) | Pharmaceutical formulation | |
| HUP0105097A2 (en) | Pharmaceutical mixtures comprising a combination of a profen and other active compounds | |
| GB9909154D0 (en) | Pharmaceutical formulation | |
| GB9822333D0 (en) | Pharmaceutical formulation | |
| GB9817470D0 (en) | Pharmaceutical formulation | |
| GB9926251D0 (en) | Pharmaceutical formulation | |
| GB9802617D0 (en) | Pharmaceutical formulation | |
| GB9810521D0 (en) | Use of an agent in the manufacture of a medicament | |
| GB9811622D0 (en) | Drug formulation | |
| SI1200118T1 (en) | A pharmaceutical formulation comprising megalatran and its prodrug | |
| GB9817217D0 (en) | Pharmaceutical formulation | |
| GB9928489D0 (en) | Pharmaceutical formulation | |
| GB9824502D0 (en) | Pharmaceutical formulation |